BioCryst Reports Third Quarter 2026 Financial Results
Globe Newswire•04/11/2026•07:00 ET
0
Key Highlights
- ➤2026 total revenue guidance raised to $715 million to $730 million
- ➤2026 ORLADEYO revenue guidance maintained at $625 million to $645 million
- ➤Q3 total revenue reached $180.3 million, up 13% year over year
- ➤Q3 operating profit rose to $53.3 million from $29.6 million
- ➤FDA approved ORLADEYO 150 mg oral pellets for patients aged 12 and older
Expert Statements
Charlie Gayer, President and Chief Executive Officer of BioCryst
“In the third quarter, we delivered continued growth of ORLADEYO and strong profitability while broadening the foundation for our long-term success. We successfully launched ORLADEYO pellets in pediatric patients, received FDA approval for their use in adolescents and adults in October, and implemented our specialty pharmacy transition to CareMed, all of which will make ORLADEYO accessible for more patients. Looking to our pipeline, BCX17725 remains on track for the early clinical data by the end of this year, and we look forward to navenibart pivotal results in the third quarter of 2027. This progress across our business increases our confidence in our ability to drive sustainable growth and lasting value for patients and shareholders.”
— Total net revenue of $180.3 million and ORLADEYO(®) net revenue of $174.8 million —
— Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million —
Get started
Create a free account to read the full story.